Journal
NATURE COMMUNICATIONS
Volume 11, Issue 1, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-020-17525-6
Keywords
-
Categories
Funding
- European Research Council (ERC) advanced grant ANGIOFAT [250021]
- Swedish Research Council
- Swedish Cancer Foundation
- Swedish Children's Cancer Foundation
- Strategic Research Areas (SFO)-Stem Cell and Regenerative Medicine Foundation
- Karolinska Institute Foundation
- Karolinska Institute distinguished professor award
- Torsten Soderbergs Foundation
- Maud and Birger Gustavsson Foundation
- NOVO Nordisk Foundation-Advance grant
- Knut and Alice Wallenberg's Foundation
- National Natural Science Foundation of China [81801163]
- Karolinska Institute
Ask authors/readers for more resources
FGF-2 displays multifarious functions in regulation of angiogenesis and vascular remodeling. However, effective drugs for treating FGF-2(+) tumors are unavailable. Here we show that FGF-2 modulates tumor vessels by recruiting NG2(+) pricytes onto tumor microvessels through a PDGFR beta -dependent mechanism. FGF-2(+) tumors are intrinsically resistant to clinically available drugs targeting VEGF and PDGF. Surprisingly, dual targeting the VEGF and PDGF signaling produces a superior antitumor effect in FGF-2(+) breast cancer and fibrosarcoma models. Mechanistically, inhibition of PDGFR beta ablates FGF-2-recruited perivascular coverage, exposing anti-VEGF agents to inhibit vascular sprouting. These findings show that the off-target FGF-2 is a resistant biomarker for anti-VEGF and anti-PDGF monotherapy, but a highly beneficial marker for combination therapy. Our data shed light on mechanistic interactions between various angiogenic and remodeling factors in tumor neovascularization. Optimization of antiangiogenic drugs with different principles could produce therapeutic benefits for treating their resistant off-target cancers. Anti-VEGF therapy has many limitations that might be resolved by using combination treatment approaches. Here, the authors demonstrate that the dual-targeting of VEGF and PDGF is required for targeting resistant FGF2+ tumors which depend on the recruitment of pericytes on tumor microvessels.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available